Baird Reiterates Buy Rating on Definium Therapeutics, Inc.
Baird maintains its buy rating on Definium Therapeutics, setting a $57 price target, a 35.30% upside from the current price.
Key Points
- On June 23, 2026, Baird reiterated its buy rating on Definium Therapeutics, Inc. (DFTX) and set a price target of $57.
- Baird's $57 price target implies 35.30% upside from Definium Therapeutics, Inc.'s ($DFTX) current $42.13 share price.
- Shares of NasdaqGS:DFTX traded near $36.67 on Tuesday, with a market cap of approximately $3.99 billion.
- Definium Therapeutics insiders, including the CEO, recently bought shares, signaling confidence in the company's prospects.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 23, 2026, Baird reiterated its buy rating on Definium Therapeutics, Inc. (NasdaqGS:DFTX), setting a price target of $57. This move by analyst Christopher Chen suggests continued confidence in the biotechnology company's potential.
Baird vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Definium Therapeutics, Inc. Stock Up 2.8%
Shares of Definium Therapeutics traded around $36.67 on Tuesday. The company has a market cap of about $3.99 billion and a forward P/E ratio that isn't meaningful due to its lack of profitability. With a beta of 2.378, the stock is more volatile than the market. Over the past year, the stock's price has ranged from $6.35 to $39.16, with a 50-day moving average of $22.61 and a 200-day moving average of $16.28. The company maintains a strong liquidity position with a current ratio of 4.69 and a quick ratio of 4.60, alongside a debt-to-equity ratio of 14.62.
$DFTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Definium Therapeutics, Inc.
Several insiders at Definium Therapeutics, including CEO Robert Barrow, recently purchased shares. On June 22, 2026, Barrow acquired 375,000 shares. Other executives, such as Chief Medical Officer Daniel Karlin and Chief Legal Officer Mark Sullivan, also bought shares. These transactions were not part of any pre-planned trading programs and suggest a bullish outlook from the management team.
Analysts Set New Price Targets
On June 23, 2026, Baird maintained its buy rating on Definium Therapeutics with a $57 price target. On the same day, Needham also maintained a buy rating with a $50 target. Leerink Partners and Oppenheimer reiterated buy ratings with targets of $52 and $60, respectively, on June 22. The consensus among 15 analysts is a strong buy, with an average price target of $39.87.
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, New York. It focuses on developing innovative treatments for brain health disorders. The company is working on DT120, which is in phase 3 trials for conditions like generalized anxiety disorder and major depressive disorder, and DT402, currently in phase 2a trials for autism spectrum disorder. Led by CEO Robert Barrow, Definium has a workforce of 105 employees.
Bottom Line
Baird's reiteration of a buy rating for Definium Therapeutics, with a $57 target, reflects ongoing confidence in the company's growth prospects. Shares have shown significant volatility, typical for biotech firms in clinical development stages. The recent insider buying activity aligns with the positive analyst sentiment, though investors should remember that analyst ratings are based on past data and market conditions can change.
Get Definium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DFTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.